DOCSLIB.ORG

The Ambassador, Head of Delegation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Ambassador, Head of Delegation Scientific Section RDI in Israel News Issue No. 286- March 201 3 Policy 2 Research Highlights 3 Events 5 Facts & Figures 5 Publications 6 International and Member State News 7 Disclaimer: RDI News is not a formal communication and does not necessarily represent the official position of the Delegation of the European Union to the State of Israel. RDI News is an internal service and is not intended as a source for further publication. Some of the material appearing in RDI News has been taken from newspapers, journals and other publications. The Delegation of the European Union to the State of Israel cannot authorize the reproduction of items taken from other publications. Those wishing to reproduce articles are advised to contact the relevant publication Contacts: [email protected] - [email protected] Policy President Barroso announces creation of a Science and Technology Advisory Council The creation of the Advisory Council follows the President’s appointment of Professor Anne Glover as the European Commission’s first Chief Scientific Adviser in January 2012, aiming at ensuring more evidence-based European Union policy-making, but also at promoting the uptake of science & technology in society, including a better transfer of knowledge from the scientific world to industry. Prof. Ada Yonath, from the Weizmann Institute, who received the Nobel Prize in Chemistry in 2009, is one of two non-EU members of the 15 member Council." http://europa.eu/rapid/press-release_IP-13-168_en.htm?locale=en Is the start-up nation sustainable? Israeli policy talks in terms of growth, not leadership, and that is no longer enough, argues Roy Keidar, CEO of the Reut Institute. http://www.globes.co.il/serveen/globes/docview.asp?did=1000825383&fid=1724 Startup exits: On-ramp to a bright future, or dead end that only lines foreigners' pockets? Is it better to sell off local startups to multinational corporations, or to grow them into big Israeli companies? That question is at the heart of one of the liveliest debates gripping the country's tech sector. Critics of the "exit approach" say it inhibits local job growth, and that Israeli companies that are sold and turned into development center for global technology players face a constant threat of closure and don’t pay enough taxes in Israel. But according to figures issued recently by the Central Bureau of Statistics, these centers increasingly contribute to the economy. In fact, during the global economic crisis at the end of the last decade these centers boosted their operations just as local R&D firms contracted…One of Israel's main sources of pride is its high rate of R&D expenditure as a percentage of gross domestic product. The business sector's internal R&D expenditure in 2009, totalling NIS 30.8 billion, came to 3.9% of GDP, putting Israel in top place worldwide. But without the development centers run by foreign companies Israel would have been fifth overall, with R&D expenditure representing just 1.92% of GDP. http://www.haaretz.com/misc/article-print-page/startup-exits-on-ramp-to-a-bright-future-or-dead- end-that-only-lines-foreigners-pockets.premium-1.514149?trailingPath=2.169%2C2.199%2C http://www1.cbs.gov.il/webpub/pub/text_page_eng.html?publ=56&CYear=2009&CMonth=1 Elbit's outgoing CEO discusses Israeli defence industry's biggest missed opportunity "The biggest missed opportunity was that the Israeli defence industry didn't consolidate" Yossi Ackerman said. "In Israel it is a difficult process with government companies, not just in defence. You need to act now while it is still in good shape. Compensate the employees, ensure their financial safety, undertake a reorganization and see to R&D. http://www.haaretz.com/misc/article-print-page/elbit-s-outgoing-ceo-discusses-israeli-defense- industry-s-biggest-missed-opportunity.premium-1.509486?trailingPath=2.169%2C2.199%2C High tech incubators to be set up in Beersheba, Ashdod The Beersheba incubator will focus on cyber, and the Ashdod incubator will nurture new media ventures. The Office of the Chief Scientist has approved several new high tech incubators, two of which will be established in the south. http://www.globes.co.il/serveen/globes/docview.asp?did=1000829919&fid=1725 Experts: Israeli farm tech is field yet to be fully exploited Despite being a world leader in agricultural R&D, Israel is falling short of leveraging its capabilities, expert says http://www.haaretz.com/misc/article-print-page/experts-israeli-farm-tech-is-field-yet-to-be-fully- exploited.premium-1.513257?trailingPath=2.169%2C2.199%2C Commercialization deals are the new exit In drug development, commercialization agreements have become the main way for new companies to create value http://www.globes.co.il/serveen/globes/docview.asp?did=1000824681&fid=1724 2 Research Highlights ENVIRONMENT AND WATER A breakthrough in solar fuels Professor Avner Rothschild and his research team from the Technion University have made a breakthrough in solar fuels. Using the power of the sun and ultrathin films of iron oxide (commonly known as rust), the researchers have found a novel way to split water molecules into hydrogen and oxygen http://www.focus.technion.ac.il/Feb13/energyStory2.asp Israeli-Palestinian team studies local water A group of Israeli and Palestinian environmental scholars have started on a joint effort to test the area’s water supply for potentially health-altering endocrine-disrupting chemicals. At their head is Prof. Alon Tal of Ben-Gurion University’s Jacob Blaustein Institute for Desert Research at Sde Boker. http://www.jpost.com/Sci-Tech/Article.aspx?id=304677 Mediterranean Sea Studies: New TAU-Ruppin Center Tel Aviv University is joining up with the Ruppin Academic Center to establish a new, multidisciplinary, Center for Mediterranean Sea Studies. The surprising discovery of major gas fields off the coast of Israel generated hope for greater energy independence, but it also highlighted the country’s lack of petroleum-related experts that could guide the efficient and environmentally responsible exploitation of this energy wealth http://english.tau.ac.il/news/mediterranean_sea_studies The powerful new antioxidant made of sun and algae A nutritional and cosmetic supplement produced at Israel’s Kibbutz Ketura is at the heart of a $50 million international deal http://israel21c.org/environment/sun-microalgae-powerful-antioxidant/ Develop technology now to fight future food shortage Erez Vigodman, former head of Strauss and current CEO of a global pesticide company, wants to see countries around the world offering incentives to entrepreneurs of agriculture technology http://www.haaretz.com/business/economy-finance/israeli-ceo-of-global-pesticide-company-develop- technology-now-to-fight-future-food-shortage-1.513101 Israeli products provide natural defence against bugs A new company from Israel called EdenShield has a natural solution for keeping greenhouses pest- free without nasty pesticides that pollute the earth and harm people http://www.ishitech.co.il/0413ar7.htm ICT Navigating through mega malls & large buildings made simple Students from the Technion developed a novel mobile indoor navigational system http://www1.technion.ac.il/_local/includes/blocks/news-items/130305-amdocs-qualcomm/news-item- en.htm Keeping your mobile virus-free A hacker sitting just a table away could be hopping onto your device as you check your email, but Israel’s Skycure has you covered http://israel21c.org/technology/keeping-your-mobile-virus-free/ Surgery without scars or scalpels Israel’s InSightec is transforming the operating room with a new ultrasound technology that enables surgeons to destroy tumours and cysts without incisions http://israel21c.org/health/surgery-without-scalpels-or-scars/ 3 Citi opens Israel data intelligence lab The lab manages the most advanced projects in capital markets, combining technological challenges in big data and related fields. http://www.globes.co.il/serveen/globes/docview.asp?did=1000833520&fid=1725 Futuristic 'microscope' sees through skin Israeli team from the Weizmann Institute of Science invents a simple new imaging tool that brings us one step closer to 'X-ray vision.' http://www.ishitech.co.il/0413ar9.htm Cyber Stranger Danger To help Facebook users protect themselves, Michael Fire and a team of Ben Gurion University student researchers have developed a Facebook app called the Social Privacy Protector (SPP). http://www.aabgu.org/media-center/bgu-making-a-difference/cyber-stranger-danger.html "We're providing building blocks for next-generation communications" Compass-EOS has unveiled the world's first silicon photonics router for the most power hungry sections of communications networks. http://www.globes.co.il/serveen/globes/docview.asp?did=1000830849&fid=1724 SPACE Israeli space engineers hope to take another giant leap for mankind Israel may not have Apollo, but its space industry is hoping to take a giant leap for mankind in 2015 to become the third country in history to land on the moon, this time in a tiny unmanned spacecraft equipped with high definition technology capable of broadcasting images back to Earth. http://www.haaretz.com/misc/article-print-page/israeli-space-engineers-hope-to-take-another-giant- leap-for-mankind.premium-1.509660?trailingPath=2.169%2C2.216%2C2.221%2C LIFE SCIENCES Ben Gurion University researchers generate promising drug candidate for psoriasis treatment Researchers have engineered a natural immune system receptor into a promising drug candidate for the treatment of Psoriasis http://in.bgu.ac.il/en/Pages/news/psoriasis_drug.aspx Technion scientists develop a new approach for artificial stimulation of blind retinas Method is based on optogenetics – a newly developing area in neuroscience, and is a first step towards non-invasive sight restoration in cases of degenerative retinal diseases http://www1.technion.ac.il/_local/includes/blocks/news-items/130227-shay213/news-item-en.htm New implant is alternative to spinal fusion Israel’s Premia Spine has a transformative solution for spinal stenosis inspired by the success of total hip and total knee replacement.
Load more

Recommended publications
  • Cv from Public Relations
    PROF. RUTH ARNON Formerly Vice-President of the Weizmann Institute of Science (1988-1997), is a world renowned Immunologist. Prof. Arnon joined the Weizmann Institute in 1960. Prior to her appointment as Vice-President, she served as Head of the Department of Chemical Immunology, and as Dean of the Faculty of Biology. From 1985 to 1994, she was the Director of the Institute's MacArthur Center for Molecular Biology of Tropical Diseases. Prof. Arnon has made significant contributions to the fields of vaccine development, cancer research and to the study of parasitic diseases. Along with Prof. Michael Sela, she developed Copaxone® a drug for the treatment of multiple sclerosis which was approved by the U.S. Food and Drug Administration, and is presently marketed in the USA, Canada the EU, Australia and many other countries worldwide. Prof. Arnon is a member of the Israel Academy of Sciences, and was the Chairperson of its Sciences division from 1995-2001 and was later elected as The Academy's Vice President. On the world scene, she is an elected member of the European Molecular Biology Organization (EMBO). She has served as President of the European Federation of Immunological Societies (EFIS), and as Secretary-General of the International Union of Immunological Societies (IUIS), and is presently a member of the European Union Research Advisory Board (EURAB) and served as the Senior Vice-President of the Association of Academies of Sciences in Asia (AASA). In 2004 Prof. Arnon served as the President of the Association of Academies of Sciences in Asia (AASA). Her awards include the Robert Koch Prize in Medical Sciences, Spain's Jiminez Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology and the Israel Prize; Tel-Hai; Honorary doctorate from the University of the Negev, Ben- Gurion.
    [Show full text]
  • Longevity Industry in Israel LANDSCAPE OVERVIEW
    Longevity Industry in Israel LANDSCAPE OVERVIEW SCIENCE, TECHNOLOGIES, COMPANIES, INVESTORS, TRENDS Longevity Industry in Israel Landscape Overview 2018 Mind Map Longevity Industry in Israel 3 Executive Summary 6 Chapter I: Israel Longevity Industry Landscape Overview 18 Сhapter II: History of Geroscience in Israel 37 Chapter III: Current State of Longevity in Israel 42 Chapter IV: Israeli Longevity Alliance (ISRLA)/VETEK 58 Chapter V: Top Universities Focusing on Longevity 61 Chapter VI: Media and Conferences 70 Chapter VII: The Policy Landscape of Longevity in Israel 76 Chapter VIII: Global Landscape Overviews from our previous reports 84 Chapter IX: The Economics of Longevity in Israel 109 APPENDIX/ PROFILES 10 Israel Longevity R&D Centers 128 10 Israel Longevity Non-Profit Organizations 141 10 Israel Longevity Conferences 154 60 Israel Longevity Influencers 167 160 Companies: Longevity in Israel 230 180 Investors: Longevity in Israel 393 Disclaimer 577 Longevity Companies - 160 Industry in Israel Personalized Investors - 180 Medicine Non-Profits - 10 Landscape 2019 R&D Centers - 10 Progressive Wellness Investors Companies Non-Profits R&D Centers Preventive Medicine AgeTech LONGEVITY Regenerative INTERNATIONAL Medicine Longevity Industry in Israel 2019 - 160 COMPANIES Drug Development Progressive wellness Gene therapies AgeTech Neurotech Others Progressive R&D Implant & Prosthetics Cell therapy Diagnostic Executive Summary Executive Summary 6 BIRAX Aging: Leapfrogging Population Ageing & Establishing A Strong Longevity Industry & R&D Landscape One of the most significant developments to occur in the Israel Longevity Industry in the past year is the formation of the BIRAX Partnership on Aging. The Britain Israel Research and Academic Exchange Partnership (BIRAX) is a multi-million pound initiative launched by the British Council, the Pears Foundation and the British Embassy in Israel, supported by both the Israeli and British Ministries of Science, to invest in research initiatives jointly undertaken by scientists in Britain and Israel.
    [Show full text]
  • Israel Prize
    Year Winner Discipline 1953 Gedaliah Alon Jewish studies 1953 Haim Hazaz literature 1953 Ya'akov Cohen literature 1953 Dina Feitelson-Schur education 1953 Mark Dvorzhetski social science 1953 Lipman Heilprin medical science 1953 Zeev Ben-Zvi sculpture 1953 Shimshon Amitsur exact sciences 1953 Jacob Levitzki exact sciences 1954 Moshe Zvi Segal Jewish studies 1954 Schmuel Hugo Bergmann humanities 1954 David Shimoni literature 1954 Shmuel Yosef Agnon literature 1954 Arthur Biram education 1954 Gad Tedeschi jurisprudence 1954 Franz Ollendorff exact sciences 1954 Michael Zohary life sciences 1954 Shimon Fritz Bodenheimer agriculture 1955 Ödön Pártos music 1955 Ephraim Urbach Jewish studies 1955 Isaac Heinemann Jewish studies 1955 Zalman Shneur literature 1955 Yitzhak Lamdan literature 1955 Michael Fekete exact sciences 1955 Israel Reichart life sciences 1955 Yaakov Ben-Tor life sciences 1955 Akiva Vroman life sciences 1955 Benjamin Shapira medical science 1955 Sara Hestrin-Lerner medical science 1955 Netanel Hochberg agriculture 1956 Zahara Schatz painting and sculpture 1956 Naftali Herz Tur-Sinai Jewish studies 1956 Yigael Yadin Jewish studies 1956 Yehezkel Abramsky Rabbinical literature 1956 Gershon Shufman literature 1956 Miriam Yalan-Shteklis children's literature 1956 Nechama Leibowitz education 1956 Yaakov Talmon social sciences 1956 Avraham HaLevi Frankel exact sciences 1956 Manfred Aschner life sciences 1956 Haim Ernst Wertheimer medicine 1957 Hanna Rovina theatre 1957 Haim Shirman Jewish studies 1957 Yohanan Levi humanities 1957 Yaakov
    [Show full text]
  • President's Report 2018
    VISION COUNTING UP TO 50 President's Report 2018 Chairman’s Message 4 President’s Message 5 Senior Administration 6 BGU by the Numbers 8 Building BGU 14 Innovation for the Startup Nation 16 New & Noteworthy 20 From BGU to the World 40 President's Report Alumni Community 42 2018 Campus Life 46 Community Outreach 52 Recognizing Our Friends 57 Honorary Degrees 88 Board of Governors 93 Associates Organizations 96 BGU Nation Celebrate BGU’s role in the Israeli miracle Nurturing the Negev 12 Forging the Hi-Tech Nation 18 A Passion for Research 24 Harnessing the Desert 30 Defending the Nation 36 The Beer-Sheva Spirit 44 Cultivating Israeli Society 50 Produced by the Department of Publications and Media Relations Osnat Eitan, Director In coordination with the Department of Donor and Associates Affairs Jill Ben-Dor, Director Editor Elana Chipman Editorial Staff Ehud Zion Waldoks, Jacqueline Watson-Alloun, Angie Zamir Production Noa Fisherman Photos Dani Machlis Concept and Design www.Image2u.co.il 4 President's Report 2018 Ben-Gurion University of the Negev - BGU Nation 5 From the From the Chairman President Israel’s first Prime Minister, David Ben–Gurion, said:“Only Apartments Program, it is worth noting that there are 73 This year we are celebrating Israel’s 70th anniversary and Program has been studied and reproduced around through a united effort by the State … by a people ready “Open Apartments” in Beer-Sheva’s neighborhoods, where acknowledging our contributions to the State of Israel, the the world and our students are an inspiration to their for a great voluntary effort, by a youth bold in spirit and students live and actively engage with the local community Negev, and the world, even as we count up to our own neighbors, encouraging them and helping them strive for a inspired by creative heroism, by scientists liberated from the through various cultural and educational activities.
    [Show full text]
  • Curriculum Vitae
    Summary Publications CURRICULUM VITAE NAME: MARK STEVEN FREEDMAN RANK: Professor of Medicine (Neurology) University of Ottawa Senior Scientist, OHRI EMPLOYEE NUMBER: 90715 OFFICE ADDRESS: 501 Smyth Road Ottawa General Hospital Ottawa, Ontario K1H 8L6 TELEPHONE (office): (613)737-8917 TELEFAX: (613)737-8857 e-mail: [email protected] (hospital) [email protected] (home) HOME ADDRESS: 1035 Bank St., suite 1903 Ottawa, Ontario K1S 5K3 HOME TELEPHONE: (613) 226-6440 CITIZENSHIP: Canadian LANGUAGES: English, French, Hebrew DATE AND PLACE OF BIRTH: May 3, 1955 Toronto, Ontario GENDER: Male MARITAL STATUS: Married with 3 children DEGREES: BSc (1976) University of Toronto (Science) Hon. BSc (1977) University of Toronto (Zoology) MSc (1980) University of Toronto (Molecular Neurochemistry) MD (1983) University of Toronto PROFESSIONAL FRCP(C) (1987) (Neurology) #373306 CERTIFICATION: CSPQ (1988) (Neurology) #12046 LICENSURE: Ontario (CPSO) #52527 Québec (CPMQ) #90009 Mark Steven FREEDMAN 2 PROFESSIONAL TRAINING: Sept 1980 - May 1982: Sunnybrook Medical Centre: Undergraduate Medical Student (years II & III) Sept 1980 - May 1982: Mount Sinai Hospital: 1 day per week for the entire year plus the entire summer in: Clinical Neurology, (Elective) Sept 1982 - Oct 1982: Institute of Neurology, The National Hospital, Queen Square (London, England): 2 month elective in Clinical Neurology June 1982 - June 1983: Mount Sinai Hospital: Clinical Clerkship June 1983 - June 1984: Sunnybrook Medical Centre: Straight internship in Internal Medicine July 1984 - Sept 1984: Toronto General Hospital: Resident in Neurology Oct. 1984 - Dec 1984: Hospital for Sick Children: Resident in Pediatric Neurology Jan. 1985 - June 1985: Wellesley Hospital: Senior Resident in Neurology July 1985 - Dec 1985: St. Michael's Hospital: Senior Resident in Neurology Jan.
    [Show full text]
  • EMBC Annual Report 2005
    EMBO | EMBC annual report 2005 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Frank Gannon, EMBO 4 preface by Susan Gasser, EMBO Council 6 preface by Marja Makarow, EMBC 8 past & present timeline 12 brief history 13 EMBO | EMBC | EMBL 14 EMBO actions 2005 17 EMBC actions 2005 19 EMBO & EMBC programmes and activities fellowship programme 23 courses & workshops programme 24 world activities 25 young investigator programme 26 women in the life sciences 27 science & society programme 28 electronic information programme 29 EMBO activities The EMBO Journal 32 EMBO reports 33 Molecular Systems Biology 34 journal subject categories 35 national science reviews 36 gold medal 37 award for communication in the life sciences 38 sectoral meetings 39 plenary lectures 40 communications offi ce 41 European Life Sciences Forum (ELSF) 42 ➔ 2 table of contents appendix EMBC delegates and advisers 46 EMBC scale of contributions 53 EMBO council members 2005 54 EMBO committee members & auditors 2005 55 EMBO council members 2006 56 EMBO committee members & auditors 2006 57 EMBO members elected in 2005 58 advisory editorial boards & senior editors 2005 66 long-term fellowship awards 2005 70 long-term fellowships: statistics 84 long-term fellowships 2005: geographical distribution 86 short-term fellowship awards 2005 88 short-term fellowships: statistics 102 short-term fellowships 2005: geographical distribution 104 young investigators 2005 106 young investigators 2000 – 2004 107 young investigators: statistics 108 young investigator lectures 2005 110 courses | workshops | conferences | symposia 2005 112 plenary lectures 2005 118 participation of women in EMBO activities: statistics 120 EMBO staff 124 events in 2006 courses | workshops | conferences | conference series | symposia 2006 128 plenary lectures 2006 134 other EMBO events 2006 136 organisations and acronyms 138 ➔ 3 preface EMBO & EMBC 2005 An awkward time warp surrounds annual 1200 applications for long-term fellowships and reports.
    [Show full text]
  • A Symposium in Honor of the 80Th Birthday of Prof. Israel Pecht
    A Symposium in Honor of the 80th Birthday of Prof. Israel Pecht June 29th, 2017 Molecular Recognition, The David Lopatie Conference Centre Signaling and Function Weizmann Institute of Science Program 14:00-15:40 - SESSION 3 Chairs: Laszlo Fesus, University of Debrecen, Debrecen, Hungary 08:30-09:00 Registration Peter Kroneck, University of Konstanz, Konstanz, Germany 14:05 Alexander Levitzki, Hebrew University, Jerusalem, Israel 09:00-09:15 - OPENING SESSION Targeting the immune system to tumours Daniel Zajfman, President, Weizmann Institute of Science, Rehovot, Israel 14:35 Maurizio Brunori, La Sapienza University, Rome, Italy Michael Sela, Weizmann Institute of Science, Rehovot, Israel Protein frustration between folding and function 09:15 -10:50 - SESSION 1 15:05-15:40 - SESSION 4 Chairs: Ulrich Kubitscheck, University of Bonn, Bonn, Germany Chair: Ruth Arnon, Weizmann Institute of Science, Rehovot, Israel Miguel de la Rosa, University of Seville, Seville, Spain 15:10 Helga Nowotny, ERA Council Forum, Vienna, Austria 09:20 Harry Gray, California Institute of Technology, California, USA Navigating uncertainty: the usefulness of useless knowledge Living with Oxygen 15:40-16:00 Coffee break 09:50 Daniella Goldfarb, Weizmann Institute of Science, Rehovot, Israel 16:00-18:00 - SESSION 5 The electron transfer mediating copper site in azurin - spectroscopic digging into its unique electronic structure Chairs: Anna Erdei, Eötvös Loránd University, Budapest, Hungary V. Horejsi, Institute of Molecular Genetics, Czech Academy of 10:20 David Cahen,
    [Show full text]
  • Honorary Awards 09
    3/4/2021 University Units - Honorary Awards http://web.bgu.ac.il/Eng/Units/associates/HonoraryAwards/ Go JUN JUL MAY ⍰ ❎ 13 captures 09 f 09 Jul 2009 - 17 Apr 2019 2008 2009 2011 ▾ About this capture Hebrew Home Page | BGU Home | The Annual Board of Governors Meeting | Senior Administration Site Donor & Associates Affairs >> Honorary Awards Honorary Awards Search Powered by Google Doctor of Philosophy Honoris Causa Named Academic Units Professorial Chairs 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 Honorary Awards 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Ben-Gurion Wall Buildings - Campus Map 2001 2002 2003 2004 2005 2006 2007 2008 Worldwide Associates Offices [ Klaus Schwab. (Jul. 09, 2009). Honorary Doctor Personnel Honorary Fellows (1999); Honorary Professor (2003). Ben-Gurion University of the Negev. Reproduced for Honorary Research Fellow educational purposes only. Fair Use relied upon. Source: https://web.archive.org/ Lifetime Achievement Award web/20090709080202/http://web.bgu.ac.il:80/Eng/ Units/associates/HonoraryAwards/ ] Honorary Professorship Doctor of Philosophy Honoris Causa 1979 1980 Aron Chilewich Lane Kirkland Prof. Haim Hanani Dr. Alec Lerner Hyman Kreitman Prof. Leo Picard Prof. Moshe Rachmilewitz Prof. Natan Rosen 1981 1982 Prof. John Beck Judge Shlomo Elkayam General Alexander M. Haig, Jr. Dr. Zoltan Toman David Tuviyahu (Posthumous) 1983 1984 Roberta Abrams Arnold Forster Prof. Michael Evenari Dr. Thomas O. Hecht Senator Edward M. Kennedy Shimon Peres Prof. Benjamin Mazar Isaac Bashevis Singer Prof. Cecil G. Sheps Barbara Tuchman Prof. Ephraim Elimelech https://web.archive.org/web/20090709080202/http://web.bgu.ac.il:80/Eng/Units/associates/HonoraryAwards/ 1/5 3/4/2021 University Units - Honorary Awards Lord Weidenfeld of Chelsea 1985 Prof.
    [Show full text]
  • Rutharnon Fellowships
    RuthArnon Fellowships מלגות רות ארנון תש"ף | 2020 Ruth Arnon Fellowships Introductory remarks Professor Nili Cohen President, Israel Academy of Sciences and Humanities Throughout her illustrious scientific career, Professor Arnon has addressed the many concerns of researchers at the Weizmann Institute in particular and in Israel in general, by serving in many influential positions, as Dean of Biology, and Vice President for Research at the Institute and more recently as President of the Israel Academy of Sciences and Humanities. In all these positions she paved the way for women as scientists and as academic leaders. The issues facing women scientists throughout their careers are of particular concern to Professor Arnon, and so she agreed to chair the Council for Higher Education’s Committee to Further Women in Israel’s Institutions of Higher Education. The committee found that the major obstacle to the advancement of women’s careers was the necessity to travel abroad for postdoctoral training. Without this experience on their curriculum vitae, they found themselves at a significant disadvantage as opposed to their male counterparts. Often they were hindered from traveling because their spouses couldn’t take the required time off from their careers, or couldn’t find employment abroad to provide the necessary supplement for their young families’ needs. Some of the women researchers are single mothers. Funding daycare for young children abroad is another expense not covered by the various postdoctoral fellowships. The Arnon Committee made several recommendations, one of which was to seek additional financial assistance for women’s postdoctoral training abroad. In 2016, setting an example to her cohorts and the system, Professor Arnon donated out of her own pocket to establish a fellowship fund under the auspices of the Israel Academy for alumnae of the Academy’s Adams Fellowships Program.
    [Show full text]
  • Constructing the Legitimacy of Research Commercialization
    Mythologizing the story of a scientific invention: Constructing the legitimacy of research commercialization Adi Sapir, Department of Leadership and Policy in Education, Faculty of Education, University of Haifa, Israel. EGOS 2018 Sub-theme 48: More to Talk About: Unexpected Roles of Language in Organizing This paper explores the processes through which an organizational story acquires mythological status within an organizational field. To this end, I analyze a story of a successful case of academic technology transfer that gained mythological status in the field of higher education in Israel: the commercialization of the innovative pharmaceutical drug Copaxone. I identify three processes of myth-making: organizational storytelling, media diffusion and reconstruction, and field-level counter-narratives. I argue that myth-making is a collective work, in which an organizational story is shaped not only through the strategic rhetorical work of managers but also through interpretations and modifications by the media and later by other actors in the field. The myth of Copaxone, as it is currently told in the field of higher education in Israel, is a complex assemblage of the organizational story and various counter-stories. I further suggest that this myth not only serves to naturalize and reinforce academic patenting, but also provides a discursive space for reflections about the ambiguities inherent in academic commercialization. Introduction This paper explores the work of mythologizing, the process through which an organizational story acquires mythological status within an organizational field. Myths are widely shared stories, often partial and distorted, that nevertheless convey an “illusion of reality” (Rawlins, 2014, p. 455). Extensive literature has shown that myths pervade organizational life (e.g.
    [Show full text]
  • 1 Ruth Arnon List of Publications
    RUTH ARNON LIST OF PUBLICATIONS A. Original Papers 1. Studies on the toxic action of thallium on the intact rat. R. Erez-Arnon and H. Meyer. Bull. Rels. Council Israel. 5A, 98 (1955). 2. The synthesis of n-carboxyanhydrides of some trifunctional amino acids without the use of protecting groups. A. Berger, J. Kurtz, T. Sadeh, A. Yaron, R. Arnon and Y. Lapidoth. Bull. Res. Council Israel. 7A, 98 (1958). 3. Studies on the chemical basis of antigenicity of proteins. 1. Antigenicity of poly-peptidyl gelatins. M. Sela and R. Arnon. Biochem. J. 75, 91 (1960). 4. Studies on the chemical basis of antigenicity of proteins. 2. Antigenicity specificity of polytyrosyl gelatins. R. Arnon and M. Sela. Biochem. J. 75, 103 (1960). 5. Studies on the chemical basis of antigenicity of proteins. 3. The role of rigidity in the antigenicity of polypeptidyl gelatins. M. Sela and R. Arnon. Biochem J. 77, 394 (1960). 6. Poly-L-cyclohexylalanine and poly-L-cyclohexylalanyl proteins. M. Sela and R. Arnon. J. Am. Chem. Soc. 82, 2625 (1960). 7. A specific synthetic polypeptide antigen. M. Sela and R. Arnon. Biochim. Biophys. Acta. 40, 382 (1960). 8. Isolation of antibodies to gelatin from antigen-antibody complex by proteolysis. R. Arnon and M. Sela. Science. 132, 86 (1960). 9. Studies on the chemical basis of the antigenicity of proteins. Synthesis, characterization and immunogeneity of some multichain and linear polypeptides containing tyrosine. M. Sela, S. Fuchs and R. Arnon. Biochem. J. 85 223 (1962). 10. The amino acid composition of chromatographically purified pepsinogen. R. Arnon and G.E.
    [Show full text]
  • The Covalent Binding of Daunomycin and Adriamycin to Antibodies, with Retention of Both Drug and Antibody Activities
    [CANCER RESEARCH 35. 1175-1181, May 1975] The Covalent Binding of Daunomycin and Adriamycin to Antibodies, with Retention of Both Drug and Antibody Activities Esther Hurwitz, Ronald Levy,1 Ruth Marón, Meir Wilchek, Ruth Arnon, and Michael Sela Departments of Chemical Immunology [E. H., R. L.. R. M.. R. A.. M. S.\ and Biophysics [M. W.] The Weizmann Institute of Science. Rehovol, Israel SUMMARY the two are linked together or, alternatively, as discussed by Isliker et al. ( 14), they might be linked in a manner allowing Daunomycin and adriamycin, two potent cancer chemo- the release of the active agent after reaching the target cell. therapeutic agents, were linked to immunoglobulins, mak Diphtheria toxin has been linked to anti-2,4-dinitrophenyl ing use of various covalent cross-linking methods. The most or anti-mumps virus antibodies, and the resulting conju suitable method for binding of the drugs to the antibodies, gates mediated a selective toxicity towards cells bearing which retained both antibody and drug activity, was perio these determinants on their surface (22, 23). In a different date oxidation of the drug, followed by the linking of the approach, the enzyme glucose oxidase was linked to anti- oxidized drug to the immunoglobulin and subsequent reduc trinitrophenyl antibodies, and these complexes were shown tion of the product with sodium borohydride. The activity of to lead to the toxic iodination of specific target cells in the the drug-antibody conjugates was tested in vitro on tumor presence of lactoperoxidase, glucose, and iodide (26). and normal cell cultures and was found to be similar to that Several reports have appeared in which complexes of of the free drug.
    [Show full text]